Last Updated : October 30, 2024
Details
FilesGeneric Name:
panitumumab
Project Status:
Complete
Therapeutic Area:
Left-sided metastatic colorectal cancer (mCRC)
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0333-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
In combination with chemotherapy, for the first-line treatment of mCRC patients with left-sided primary tumours that express wild-type RAS.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | July 13, 2023 |
|---|---|
| Call for patient/clinician input closed | September 01, 2023 |
| Clarification: - Patient input submission received from Colorectal Cancer Canada and Colorectal Cancer Resource & Action Network (CCRAN) | |
| Call for industry input open | July 13, 2023 |
| Call for industry input closed | September 01, 2023 |
| Submission received | May 19, 2023 |
| Review initiated | July 18, 2023 |
| Expert committee meeting (initial) | February 01, 2024 |
| Draft recommendation posted for stakeholder feedback | February 28, 2024 |
| End of feedback period | March 13, 2024 |
| Final recommendation posted | April 18, 2024 |
| CADTH review report(s) posted | July 29, 2024 |
Files
Last Updated : October 30, 2024